Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why United Therapeutics Corporation Stock Skyrocketed

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of United Therapeutics (NASDAQ: UTHR  ) , a biopharmaceutical company that develops products to treat chronic and life-threatening diseases primarily in the cardiopulmonary field, surged 29% today after receiving a favorable legal decision regarding its lead drug, Remodulin.

So what: According to United Therapeutics' late afternoon press release, the U.S. District Court for the District of New Jersey issued a ruling in favor of United Therapeutics in its patent case against Novartis' (NYSE: NVS  ) generic drug subsidiary Sandoz International. Sandoz had been planning to bring a generic version of Remodulin, a drug that treats breathing problems in patients with pulmonary arterial hypertension, to market, as noted by its abbreviated new drug application filing in 2011. However, those plans have changed with this ruling that upheld United Therapeutics' exclusivity claims to Remodulin in the U.S. until October 2017.

Now what: The scope of the move higher makes sense from the standpoint of United Therapeutics' shareholders because Remodulin made up $138.2 million, or 43%, of its $322.8 million in sales during the second quarter. This was up 11.1% from the year-ago period. In other words, an unfavorable ruling could have removed about a third of United Therapeutics' revenue within a year, since generics often garner about 80% to 90% of eventual sales from innovator drugs.

The good news here is United Therapeutics is free and clear to continue selling its high-margin lead drug for another three years. On the flipside, investors, or those on the outside looking in and thinking about investing in United Therapeutics, should also realize that its largest drug is going to face generic competition in just over three years. Put plainly, if investors don't have confidence in United Therapeutics' pipeline or other existing products to make up for the eventual loss of exclusivity on Remodulin, then chasing the stock higher after today may not be the best idea.

United Therapeutics may offer plenty of growth potential, but this revolutionary new technology could wind up leaving it in the dust! 
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Read/Post Comments (0) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3087200, ~/Articles/ArticleHandler.aspx, 9/4/2015 11:46:14 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Sean Williams

A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and in investment planning topics. You'll usually find him writing about Obamacare, marijuana, developing drugs, diagnostics, and medical devices, Social Security, taxes, or any number of other macroeconomic issues.

Today's Market

updated 2 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:01 PM
NVS $94.55 Down -0.81 -0.85%
Novartis CAPS Rating: ****
UTHR $149.21 Down -0.75 -0.50%
United Therapeutic… CAPS Rating: ****